Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) stock is in focus as Xencor (XNCR)-partnered lymphoma drug Monjuvi, as part of a combination regimen, lifts cancer-free survival by 25%. Read more here.

Fintel reports that on October 30, 2024, B of A Securities upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to Buy. As of October 22, 2024, the average one-year price target for Incyte ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Incyte Corporation ( NASDAQ:INCY ) announced strong profits, but the stock was stagnant. Our analysis suggests ...

These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps. Also Read: Incyte’s Jakafi Demand Is Strong, Analyst Upgrades Stock Enrollment in the ...

Investors in Incyte Corporation (Symbol: INCY) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

On Saturday, Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...